Antitumor Activity of Ganoderma Spore Oil-lycopene Complex
Article
Figures
Metrics
Preview PDF
Reference
Related
Cited by
Materials
Abstract:
The in vitro and in vivo antitumor activities of Ganoderma lucidum spore oil-lycopene complex (LZFQ), and its mechanism of action in A549 cells were investigated. The MTT method was used to measure the viability of human non-small cell lung cancer cells (A549), human gastric cancer cells (BGC823), human breast cancer cells (MCF-7) and human colon cancer cells (HCT116). A nude mouse transplanted tumor model was established to study the in vivo inhibitory effect of LZFQ on tumor. The changes in apoptosis and the expression of apoptosis-related proteins were examined by flow cytometry, and its anti-tumor mechanism was preliminarily explored. In vitro cell viability experiments showed that LZFQ had certain inhibitory effects on the growth of four kinds of tumor cells, with its inhibition on A549 cells being the greatest (IC50=0.49 mg/mL). Flowcytometry experiments showed that LZFQ could induce apoptosis in a concentration-dependent manner. Western blot experiments showed that LZFQ could reduced the level of anti-apoptotic protein Bcl-2 and increased the levels of pro-apoptotic proteins Bax and Caspase-3 in a concentration-dependent manner. The nude mice transplanted tumor experiments showed that when LZFQ was administered at doses of 2.00 g/kg (high dose group), 1.00 g/kg (medium dose group) and 0.50 g/kg (low dose group), the inhibition rates of transplanted tumor in nude mice were 60.58%, 51.92% and 43.27% respectively, with significant differences detected between the high-/medium-/low-dose groups and the model group (p<0.01). Mechanism studies showed that LZFQ could induce apoptosis in a concentration-dependent manner, and induce apoptosis by affecting the expressions of apoptosis-related proteins. The research results show that LZFQ has a certain anti-tumor effect, which can provide an experimental basis for the research and development of Ganoderma lucidum spore oil products.
